Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
HENDERSON, Nev., May 01, 2018 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion. Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.
“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP. “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”
About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/
About United Health Products, Inc.
United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464
